STAT June 21, 2024
Jason Mast, Matthew Herper

For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.

On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA approves 1st monotherapy drug for treatment-resistant depression
FDA's AI Lifecycle & Scientific Information Guidance Documents
Opinion: Three former FDA officials: Here’s what Trump and his nominees need to know
Inflammatix Scores FDA Approval for Precision Infection Test
FDA Approves Spravato as Monotherapy for Major Depressive Disorder

Share This Article